Gastroenterology
Volume 127, Issue 1 , Pages 310-330 , July 2004

A critical review of the diagnosis and management of Barrett’s esophagus: the AGA Chicago Workshop1

  • Prateek Sharma

      Affiliations

    • University of Kansas School of Medicine and VA Medical Center, Kansas City, Missouri, USA
    • Corresponding Author InformationAddress requests for reprints to: Prateek Sharma, M.D., Associate Professor of Medicine, University of Kansas School of Medicine, Department of Veterans Affairs Medical Center, 4801 E. Linwood Boulevard, Kansas City, Missouri 64128-2295, USA; fax: (816) 922-4692
    • ,
  • Kenneth McQuaid

      Affiliations

    • University of California and VA Medical Center, San Francisco, California, USA
    • ,
  • John Dent

      Affiliations

    • Royal Adelaide Hospital and University of Adelaide, Adelaide, Australia
    • ,
  • M.Brian Fennerty

      Affiliations

    • Oregon Health & Science University and VA Medical Center, Portland, Oregon, USA
    • ,
  • Richard Sampliner

      Affiliations

    • Southern Arizona VA Health Care System and Arizona Health Sciences Center, Tucson, Arizona, USA
    • ,
  • Stuart Spechler

      Affiliations

    • University of Texas Southwestern and VA Medical Center, Dallas, Texas, USA
    • ,
  • Alan Cameron

      Affiliations

    • Mayo Clinic, Rochester, Minnesota, USA
    • ,
  • Douglas Corley

      Affiliations

    • University of California, San Francisco, California, USA
    • ,
  • Gary Falk

      Affiliations

    • Cleveland Clinic Foundation, Cleveland, Ohio, USA
    • ,
  • John Goldblum

      Affiliations

    • Cleveland Clinic Foundation, Cleveland, Ohio, USA
    • ,
  • John Hunter

      Affiliations

    • Oregon Health & Science University and VA Medical Center, Portland, Oregon, USA
    • ,
  • Janusz Jankowski

      Affiliations

    • Royal Infirmary, Leicester, United Kingdom
    • ,
  • Lars Lundell

      Affiliations

    • Huddinge Hospital, Stockholm, Sweden
    • ,
  • Brian Reid

      Affiliations

    • Fred Hutchinson Cancer Center, Seattle, Washington, USA
    • ,
  • Nicholas J. Shaheen

      Affiliations

    • University of North Carolina, Chapel Hill, North Carolina, USA
    • ,
  • Amnon Sonnenberg

      Affiliations

    • Oregon Health & Science University and VA Medical Center, Portland, Oregon, USA
    • ,
  • Kenneth Wang

      Affiliations

    • Mayo Clinic, Rochester, Minnesota, USA
    • ,
  • Wilfred Weinstein

      Affiliations

    • University of California, Los Angeles, California, USA

Received 18 December 2003 ,Accepted 1 April 2004.

References 

  1. Devesa SS, Blot WJ, Fraumeni JF. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer. 1988;83:2049–2053
  2. Brown LM, Devesa SS. Epidemiologic trends in esophageal and gastric cancer in the United States. Surg Oncol Clin N Am. 2002;11:235–256
  3. Barrett NR. Chronic peptic ulcer of the oesophagus and “esophagitis.”. Br J Surg. 1950;38:175–182
  4. Practice Parameters Committee ACG Sampliner RE. Updated guidelines for the diagnosis, surveillance and therapy of Barrett’s esophagus. Am J Gastroenterol. 2002;97:1888–1895
  5. Dent J, Brun A, Fendrick M, Fennerty MB, Janssens J, Kahrilas P, et al. An evidence based appraisal of reflux disease management-The Geneval workshop report. Gut. 1999;44(suppl 2):S1–S16
  6. Naef AP, Savary M, Ozello L. Columnar-lined lower esophagus: an acquired lesion with malignant predisposition. Report on 140 cases of Barrett’s esophagus with 12 adenocarcinoma. J Thorac Cardiovasc Surg. 1975;70:826–835
  7. Winters C, Spurling TJ, Chobanian S, Curtis DJ, Esposito RL, Hacker JF, et al  Barrett’s esophagus. A prevalent occult complication of gastroesophageal reflux disease. Gastroenterology. 1987;92:118–124
  8. Sampliner RE, Garewal HS, Fennerty MB, Aickin M. Lack of impact of therapy on extent of Barrett’s esophagus in 67 patients. Dig Dis Sci. 1990;35:93–96
  9. Kim SL, Waring JP, Spechler SJ, Sampliner RE, Doos WG, Krol WF, et al. Diagnostic inconsistencies in Barrett’s esophagus. Gastroenterology. 1994;107:945–949
  10. Ofman JJ, Shaheen NJ, Desai AA, Moody B, Bozymski EM, Weinstein WM. The quality of care in Barrett’s esophagus (endoscopist and pathologist practices). Am J Gastroenterol. 2001;96:876–881
  11. Fass R, Sampliner RE. Extension of squamous epithelium into the proximal stomach—a newly recognized mucosal abnormality. Endoscopy. 2000;32:27–32
  12. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999;340:825–831
  13. Theisen J, Stein HJ, Dittler HJ, Feith M, Moebius C, Kauer WK, et al. Prospective chemotherapy unmasks underlying Barrett’s mucosa in patients with adenocarcinoma of the distal esophagus. Surg Endosc. 2002;671–673
  14. Schmidt HG, Riddell RH, Walther B, Skinner DB, Riemann JF. Dysplasia in Barrett’s Esophagus. Cancer Res Clin Oncol. 1985;110:145–152
  15. Hamilton SR, Smith RRL. The relationship between columnar epithelial dysplasia and invasive adenocarcinoma arising in Barrett’s esophagus. Am J Clin Pathol. 1987;87:301–312
  16. Haggitt RC, Tryzelaar J, Ellis FH, Colcher H. Adenocarcinoma complicating columnar epithelium-lined (Barrett’s) esophagus. Am J Clin Pathol. 1978;70:1–5
  17. Skinner DB, Walther BC, Riddell RH, Schmidt H, Iascone C, DeMeester TR. Barrett’s esophagus. Comparison of benign and malignant cases. Ann Surg. 1983;198:554–566
  18. Smith RRL, Hamilton SR, Boitnott JK, Rogers EL. The spectrum of carcinoma arising in Barrett’s esophagus. Am J Surg Pathol. 1984;8:563–573
  19. Rosenberg JC, Budev H, Edwards RC, Singal S, Steiger Z, Sundareson AS. Analysis of adenocarcinoma in Barrett’s esophagus utilizing a staging system. Cancer. 1985;55:1353–1360
  20. Paraf F, Flejou JF, Pignon JP. Surgical pathology of adenocarcinoma arising in Barrett’s esophagus. Am J Surg Pathol. 1995;19:183–191
  21. Paull A, Trier JS, Dalton MB, Camp RC, Loeb P, Goyal RK. The histologic spectrum of Barrett’s esophagus. N Engl J Med. 1976;295:476–480
  22. Jass JR. Mucin histochemistry of the columnar epithelium of the esophagus. J Clin Pathol. 1981;34:866–870
  23. Lee RG. Mucins in Barrett’s esophagus (a histochemical study). Am J Clin Pathol. 1984;81:500–503
  24. Peuchmaur M, Potet F, Goldfain D. Mucin histochemistry of the columnar epithelium of the esophagus (Barrett’s esophagus) (a prospective study). J Clin Pathol. 1984;37:607–610
  25. Levine DS, Rubin CE, Reid BJ, Haggitt RC. Specialized metaplastic columnar epithelium in Barrett’s esophagus (a comparative transmission electronic microscopic study). Lab Invest. 1989;60:418–432
  26. Haggitt RC. Barrett’s esophagus, dysplasia and adenocarcinoma. Hum Pathol. 1994;25:982–993
  27. Alikhan M, Rex D, Khan A, Rahmani E, Cummings O, Ulbright TM. The variable pathologic interpretation of columnar-lined esophagus by general pathologists in community practice. Gastrointest Endosc. 1999;50:23–26
  28. Sharma P, Morales TG, Sampliner RE. Short-segment Barrett’s esophagus—the need for standardization of the definition and of endoscopic criteria. Am J Gastroenterol. 1998;93:1033–1036
  29. Sharma P, Weston AP, Morales T, Topalovski M, Mayo MS, Sampliner RE. Relative risk of dysplasia for patients with intestinal metaplasia in the distal oesophagus and in the gastric cardia. Gut. 2000;46:9–13
  30. Ormsby AH, Goldblum JR, Rice TW, Richter JE, Falk GW, Vaezi MF, et al. Cytokeratin subsets can reliably distinguish Barrett’s esophagus from intestinal metaplasia of the stomach. Hum Pathol. 1999;30:288–294
  31. Ormsby AH, Vaezi MF, Richter JE, Goldblum JR, Rice TW, Falk GW, et al. Cytokeratin immunoreactivity patterns in the diagnosis of short-segment Barrett’s esophagus. Gastroenterology. 2000;119:683–690
  32. Couvelard A, Cauvin J-M, Goldfain D, Rotenberg A, Robaszkiewicz M, Flejou JF  Groupe d’Etude l’Oesophage de Barrett . Cytokeratin immunoreactivity of intestinal metaplasia at the normal oesophagogastric junction indicates its aetiology. Gut. 2001;49:761–766
  33. Wallner B, Sylvan A, Janunger KG, Bozoky B, Stenling R. Immunohistochemical markers for Barrett’s esophagus and associations to esophageal Z-line appearance. Scand J Gastroenterol. 2001;9:910–915
  34. El-Zimaity HM, Graham DY. Cytokeratin subsets for distinguishing Barrett’s esophagus from intestinal metaplasia in the cardia using endoscopic biopsy specimens. Am J Gastroenterol. 2001;96:1378–1382
  35. Mohammed IA, Streutker CJ, Riddell RH. Utilization of cytokeratins 7 and 20 does not differentiate between Barrett’s esophagus and gastric cardiac intestinal metaplasia. Mod Pathol. 2002;15:611–616
  36. Glickman JN, Wang H, Das KM, Goyal RK, Spechler SJ, Antonioli D, et al. Phenotype of Barrett’s esophagus and intestinal metaplasia of the distal esophagus and gastroesophageal junction. An immunohistochemical study of cytokeratins 7 and 20, Das-1 and 45M1. Am J Surg Pathol. 2001;25:87–94
  37. Wallner B, Sylvan A, Stenling R, Janunger KG. The Z-line appearance and prevalence of intestinal metaplasia among patients without symptoms or endoscopical signs indicating gastroesophageal reflux. Surg Endosc. 2001;15:886–889
  38. Wallner B, Sylvan A, Janunger KG. Endoscopic assessment of the “Z-line” (squamocolumnar junction) appearance (reproducibility of the ZAP classification among endoscopists). Gastrointest Endosc. 2002;55:65–69
  39. Cameron AJ, Lomboy CT, Pera M, Carpenter HA. Adenocarcinoma of the esophagogastric junction and Barrett’s esophagus. Gastroenterology. 1995;109:1541–1546
  40. Spechler SJ. Clinical practice. Barrett’s Esophagus. N Engl J Med. 2002;346:836–842
  41. Yamamoto AJ, Levine MS, Katzka DA, Furth EE, Rubesin SE, Laufer I. Short-segment Barrett’s esophagus (findings on double-contrast esophagography in 20 patients). AJR Am J Roentgenol. 2001;176:1173–1178
  42. Gerson LB, Edson R, Lavori PW, Triadafilopoulos G. Use of a simple symptom questionnaire to predict Barrett’s esophagus in patients with symptoms of gastroesophageal reflux. Am J Gastroenterol. 2001;96:2005–2012
  43. Chandrasoma PT, Der R, Dalton P, Kobayashi G, Ma Y, Peters J, et al. Distribution and significance of epithelial types in columnar-lined esophagus. Am J Surg Pathol. 2001;25:1188–1193
  44. Jones TF, Sharma P, Daaboul B, Cherian R, Mayo M, Topalovski M, et al. Yield of intestinal metaplasia in patients with suspected short-segment Barrett’s esophagus (SSBE) on repeat endoscopy. Dig Dis Sci. 2002;47:2108–2111
  45. Oberg S, DeMeester TR, Peters JH, Hagen JA, Nigro JJ, DeMeester SR, et al. The extent of Barrett’s esophagus depends on the status of the lower esophageal sphincter and the degree of esophageal acid exposure. J Thorac Cardiovasc Surg. 1999;117:572–580
  46. Oberg S, Peters JH, DeMeester TR, Lord RV, Johansson J, DeMeester SR, et al. Determinants of intestinal metaplasia within the columnar-lined esophagus. Arch Surg. 2000;135:651–666
  47. Csendes A, Smok G, Quiroz J, Burdiles P, Rojas J, Castro C, et al. Clinical, endoscopic, and functional studies in 408 patients with Barrett’s esophagus, compared to 174 cases of intestinal metaplasia of the cardia. Am J Gastroenterol. 2002;97:554–560
  48. Rudolph RE, Vaughan TL, Storer BE, Haggitt RC, Rabinovitch PS, Levine DS, et al. Effect of segment length on risk for neoplastic progression in patients with Barrett esophagus. Ann Intern Med. 2000;132:612–620
  49. Weston AP, Badr AS, Hassanein RS. Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett’s multifocal high-grade dysplasia or adenocarcinoma. Am J Gastroenterol. 1999;94:3413–3419
  50. Menke-Pluymers MB, Hop WC, Dees J, van Blankenstein M, Tilanus HW. Risk factors for the development of an adenocarcinoma in columnar-lined (Barrett) esophagus. The Rotterdam Esophageal Tumor Study Group. Cancer. 1993;72:1155–1158
  51. Goldblum JR. The significance and etiology of intestinal metaplasia of the esophagogastric junction. Ann Diagn Pathol. 2002;6:67–73
  52. Johnson MH, Hammond AS, Laskin W, Jones DM. The prevalence and clinical characteristics of short segments of specialized intestinal metaplasia in the distal esophagus on routine endoscopy. Am J Gastroenterol. 1996;91:1507–1511
  53. Nandurkar S, Talley NJ. Barrett’s esophagus (the long and the short of it). Am J Gastroenterol. 1999;94:30–40
  54. Tytgat GNJ. Endoscopic features of the columnar-lined esophagus. Gastroenterol Clin N Am. 1997;26:507–517
  55. Spechler SJ, Zeroogian JM, Antonioli DA, Wang HH, Goyal RK. Prevalence of metaplasia at the gastro-oesophageal junction. Lancet. 1994;344:1533–1536
  56. Falk GW. Screening and surveillance of Barrett’s esophagus. In:  Sharma P,  Sampliner RE editor. Barrett’s esophagus and esophageal adenocarcinoma. Malden, Massachusetts: Blackwell Science; 2001;
  57. McClave SA, Boyce HW, Gottfried MR. Early diagnosis of columnar-lined esophagus (a new endoscopic diagnostic criterion). Gastrointest Endosc. 1987;33:413–416
  58. Dacosta R, Wilson BC, Marcon NE. New optical technologies for earlier endoscopic diagnosis of premalignant gastrointestinal lesions. J Gastroenterol Hepatol. 2002;17(suppl):S85–S104
  59. Canto MI, Setrakian S, Willis J, Chak A, Petras R, Powe NR, et al. Methylene-blue directed biopsies improve detection of intestinal metaplasia and dysplasia in Barrett’s esophagus. Gastrointest Endosc. 2000;51:560–568
  60. Sharma P, Weston AP, Topalovski M, Cherian R, Bhattacharyya A, Sampliner RE. Magnification chromoendoscopy for the detection of intestinal metaplasia and dysplasia in Barrett’s esophagus. Gut. 2003;52:24–27
  61. Ortner MA, Ebert B, Hein E, Zumbusch K, Nolte D, Sukowski U, et al. Time gated fluorescence spectroscopy in Barrett’s esophagus. Gut. 2003;52:28–33
  62. Wallace MB, Perelman LT, Backman V, Crawford JM, Fitzmaurice M, Seiler M, et al. Endoscopic detection of dysplasia in patients with Barrett’s esophagus using light-scattering spectroscopy. Gastroenterology. 2000;119:677–682
  63. Hirota WK, Loughney TM, Lazas DJ, Maydonovitch CL, Rholl V, Wong RKH. Specialized intestinal metaplasia, dysplasia and cancer of the esophagus and esophagogastric junction (prevalence and clinical data). Gastroenterology. 1999;116:277–285
  64. Ruol A, Parenti A, Zaninotto G, Merigliano S, Costantini M, Cagol M, et al. Intestinal metaplasia is the probable common precursor of adenocarcinoma in Barrett esophagus and adenocarcinoma of the gastric cardia. Cancer. 2000;88:2520–2528
  65. Cameron AJ, Souto EO, Smyrk TC. Small adenocarcinomas of the esophagogastric junction (association with intestinal metaplasia and dysplasia). Am J Gastroenterol. 2002;97:1375–1380
  66. Trudgill NJ, Suvarna SK, Kapur KC, Riley SA. Intestinal metaplasia at the squamocolumnar junction in patients attending for diagnostic gastroscopy. Gut. 1997;41:585–589
  67. Hameeteman W, Tytgat GNJ, Houthoff HJ, van den Tweel JG. Barrett’s esophagus (development of dysplasia and adenocarcinoma). Gastroenterology. 1989;96:1249–1256
  68. Miros M, Kerlin P, Walker N. Only patients with dysplasia progress to adenocarcinoma in Barrett’s esophagus. Gut. 1991;32:1441–1446
  69. Iftikhar SF, James PD, Steele RJC, Hardcastle JD, Atkinson M. Length of Barrett’s esophagus (and important factor in the development of dysplasia and adenocarcinoma). Gut. 1992;33:1155–1158
  70. Spechler SJ, Zeroogian JM, Wang HH, Antonioli DA, Goyal RK. The frequency of specialized intestinal metaplasia at the squamo-columnar junction varies with the extent of columnar epithelium lining the esophagus. Gastroenterology. 1995;108:A224
  71. Oberg S, Johansson J, Wenner J, Johnsson F, Zilling T, von Holstein CS, et al. Endoscopic surveillance of columnar-lined esophagus. Frequency of intestinal metaplasia detection and impact of antireflux surgery. Ann Surg. 2001;234:619–626
  72. Shaheen N, Ransohoff DF. Gastroesophageal reflux, Barrett’s esophagus and esophageal cancer. JAMA. 2002;287:1972–1981
  73. Cameron AJ, Lomboy CT. Barrett’s esophagus. Age, prevalence and the extent of columnar epithelium. Gastroenterology. 1992;103:1241–1245
  74. Cameron AJ, Zinsmeister AR, Ballard DJ, Carney JA. Prevalence of columnar-lined (Barrett’s) esophagus (comparison of population-based clinical and autopsy findings). Gastroenterology. 1990;99:918–922
  75. Gerson LB, Shetler K, Triadafilopoulos G. Prevalence of Barrett’s esophagus in asymptomatic individuals. Gastroenterology. 2002;123:461–467
  76. Rex DK, Cummings OW, Shaw M, Cumings MD, Wong RK, Vasudeva RS, et al. Screening for Barrett’s esophagus in colonoscopy patients with and without heartburn. Gastroenterology. 2003;125:1670–1677
  77. Mann NS, Tsai MF, Nair PK. Barrett’s esophagus in patients with symptomatic reflux esophagitis. Am J Gastroenterol. 1989;84:1494–1496
  78. Winters C, Spurling TJ, Chobanian SJ, Curtis DJ, Esposito RL, Hacker JF, et al  Barrett’s esophagus. A prevalent occult complication of gastroesophageal reflux disease. Gastroenterology. 1987;92:118–124
  79. Lieberman DA, Oehlke M, Helfand M. Risk factors for Barrett’s esophagus in community-based practice. Am J Gastroenterol. 1997;92:1293–1297
  80. Avidan S, Sonnenberg A, Schnell TG, Sontag SJ. There are no reliable symptoms for erosive esophagitis and Barrett’s esophagus (endoscopic diagnosis is still essential). Aliment Pharmacol Ther. 2002;16:735–742
  81. Gopal DV, Lieberman DQ, Magaret N, Fennerty MB, Sampliner RE, Garewal HS, et al. Risk factors for dysplasia in patients with Barrett’s esophagus. Results from a multi-center consortium. Dig Dis Sci. 2003;48:1537–1541
  82. Drewitz DJ, Sampliner RE, Garewal HS. The incidence of adenocarcinoma in Barrett’s esophagus (a prospective study of 170 patients followed 4.8 years). Am J Gastroenterology. 1997;92:212–215
  83. Sharma P, Reker D, Falk GW, Johnston M, Weston AP, Sampliner RE. Progression of Barrett’s esophagus to high-grade dysplasia and cancer (Preliminary results of the BEST trial). Gastroenterology. 2001;120:A16
  84. van Sandwick J, van Lanschot J, Kuiken B. Impact of endoscopic biopsy surveillance of Barrett’s oesophagus on pathological stage and clinical outcome of Barrett’s carcinoma. Gut. 1998;43:216–222
  85. Corley DA, Levin TR, Habel LA. Surveillance and survival in Barrett’s adenocarcinomas (a population-based study). Gastroenterology. 2002;122:633–640
  86. Provenzale D, Kemp JA, Arora S, Wong JB. A guide for surveillance of patients with Barrett’s esophagus. Am J Gastroenterology. 1994;89:670–680
  87. Nebel OT, Fornes MF, Castell DO. Symptomatic gastroesophageal reflux (incidence and precipitating factors). Am J Dig Dis. 1976;21:953–956
  88. Eckardt VF, Kanzler G, Bernhard G. Life expectancy and cancer risk in patients with Barrett’s esophagus (a prospective controlled investigation). Am J Med. 2001;11:33–37
  89. Van der Veen AH, Dees J, Blankensteijn JD, Van Blankenstein M. Adenocarcinoma in Barrett’s oesophagus (an overrated risk). Gut. 1989;30:14–18
  90. Cameron AJ, Ott BJ, Payne WS. The incidence of adenocarcinoma in columnar-lined (Barrett’s) esophagus. N Engl J Med. 1985;313:857–859
  91. Chow WH, Finkle WD, McLaughlin JK, Frankl H, Ziel HK, Fraumeni JF. The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia. JAMA. 1995;274:474–477
  92. Farrow DC, Vaughan TL, Sweeney C, Gammon MD, Chow WH, Risch HA, et al. Gastroesophageal reflux disease, use of H2 receptor antagonists, and risks of esophageal and gastric cancer. Cancer Causes Control. 2000;11:231–238
  93. Lagergren J, Ye W, Bergstrom R, Nyren O. Utility of endoscopic screening for upper gastrointestinal adenocarcinoma. JAMA. 2000;284:961–962
  94. Inadomi JM, Sampliner R, Lagergren J, Lieberman D, Fendrick AM, Vakil N. Screening and surveillance for Barrett esophagus in high-risk groups (a cost-utility analysis). Ann Intern Med. 2003;138:176–186
  95. Soni A, Sampliner RE, Sonnenberg A. Screening for high-grade dysplasia in gastroesophageal reflux disease (is it cost-effective?). Am J Gastroenterol. 2000;95:2086–2093
  96. Eisen GM, Sandler RS, Murray S, Gottfried M. The relationship between gastroesophageal reflux disease and its complications with Barrett’s esophagus. Am J Gastroenterol. 1997;92:27–31
  97. Avidan B, Sonnenberg A, Schnell TG, Sontag SJ. Hiatal hernia and acid reflux frequency predict presence and length of Barrett’s esophagus. Dig Dis Sci. 2002;47:256–264
  98. Conio M, Filiberti R, Blanchi S, Ferraris R, Marchi S, Ravelli P, et al. Risk factors for Barrett’s esophagus (a case-control study). Int J Cancer. 2002;97:225–229
  99. O’Connor JB, Falk GW, Richter JE. The incidence of adenocarcinoma and dysplasia in Barrett’s esophagus (report on the Cleveland Clinic Barrett’s Esophagus Registry). Am J Gastroenterol. 1999;94:2037–2042
  100. Cameron AJ. Barrett’s esophagus (prevalence and size of hiatal hernia). Am J Gastroenterol. 1999;94:2054–2059
  101. Cameron AJ. Epidemiology of Barrett’s esophagus and adenocarcinoma. Dis Esophagus. 2002;15:106–108
  102. U.S. Census Bureau . Current Population Survey, March 2000, Racial Statistics Branch, Population Division. 2001; Internet Release date: February 22
  103. Eloubeidi MA, Provenzale D. Does the patient have Barrett’s esophagus? The utility of predicting Barrett’s esophagus at the index endoscopy. Am J Gastroenterol. 1999;94:937–943
  104. Sorbi D, Gostout CJ, Henry J, Lindor KD. Unsedated small-caliber esophagogastroduodenoscopy (EGD) versus conventional EGD (a comparative study). Gastroenterology. 1999;117:1301–1307
  105. Saeian K, Staff DM, Vasilopoulos S, Townsend WF, Almagro UA, Komorowski RA, et al. Unsedated transnasal endoscopy accurately detects Barrett’s metaplasia and dysplasia. Gastrointest Endosc. 2002;56:472–478
  106. Falk GW, Chittajallu R, Goldblum JR, Biscotti CV, Geisinger KR, Petras RE, et al. Surveillance of Barrett’s esophagus for dysplasia and cancer with balloon cytology. Gastroenterology. 1997;112:1787–1797
  107. Rader AE, Faigel DO, Ditomasso J, Margaret N, Burm M, Fennerty MB. Cytologic screening for Barrett’s esophagus using a prototype flexible mesh catheter. Dig Dis Sci. 2001;46:2681–2686
  108. Van der Burgh A, Dees J, Hop WC, van Blankenstein M. Oesophageal cancer is an uncommon cause of death in patients with Barrett’s oesophagus. Gut. 1996;39:5–8
  109. Fitzgerald RC, Saeed IT, Khoo D, Farthing MJG, Burnham WR. Rigorous surveillance protocol increases detection of curable cancers associated with Barrett’s esophagus. Dig Dis Sci. 2001;46:1892–1898
  110. Macdonald CE, Wicks AC, Playford RJ. Final results from 10-year cohort of patients undergoing surveillance for Barrett’s oesophagus (observational study). BMJ. 2000;321:1252–1255
  111. Nilsson J, Skobe V, Johansson J, Willen R, Johnsson F. Screening for oesophageal adenocarcinoma (an evaluation of a surveillance program for columnar metaplasia of the oesophagus). Scand J Gastroenterol. 2000;35:10–16
  112. Peters JH, Clark GWB, Ireland AP, Chandrasoma P, Smyrk TC, DeMeester TR. Outcome of adenocarcinoma arising in Barrett’s esophagus in endoscopically surveyed and nonsurveyed patients. J Thorac Cardiovasc Surg. 1994;108:813–822
  113. Provenzale D, Schmitt C, Wong JB. Barrett’s esophagus (a new look at surveillance based on emerging estimates of cancer risk). Am J Gastroenterol. 1999;94:2043–2053
  114. Streitz JM, Andrews CW, Ellis JRFH. Endoscopic surveillance of Barrett’s esophagus—does it help?. J Thorac Cardiovasc Surg. 1993;105:383–388
  115. Shaheen NJ, Provenzale D, Sandler RS. Upper endoscopy as a screening and surveillance tool in esophageal adenocarcinoma. Am J Gastroenterol. 2002;97:1319–1327
  116. Sonnenberg A, Soni A, Sampliner RE. Medical decision analysis of endoscopic surveillance of Barrett’s esophagus to prevent esophageal adenocarcinoma. Aliment Pharm Ther. 2002;16:41–50
  117. Reid BJ, Levine DS, Longton G, Blount PL, Rabinovitch PS. Predictors of progression to cancer in Barrett’s esophagus (baseline histology and flow cytometry identify low- and high-risk patient subsets). Am J Gastroenterol. 2000;95:1669–1676
  118. Robertson CS, Mayberry JF, Nicholson DA, James PD, Atkinson M. Value of endoscopic surveillance in the detection of neoplastic change in Barrett’s oesophagus. Br J Surg. 1988;75:760–763
  119. Schnell TG, Sontag SJ, Chejfec G, Aranha G, Metz A, O’Connell S, et al. Long-term nonsurgical management of Barrett’s esophagus with high-grade dysplasia. Gastroenterology. 2001;120:1607–1619
  120. Sharma P, Weston A, Falk G, Johnston M, Reger D, Sampliner R. Can two upper endoscopies negative for dysplasia eliminate the need for future surveillance in patients with Barrett’s esophagus?. Am J Gastroenterol. 2001;96:S36
  121. Weston AP, Krmpotich PT, Cherian R, Dixon A, Topalosvki M. Prospective long-term endoscopic and histological follow-up of short segment Barrett’s esophagus (comparison with traditional long segment Barrett’s esophagus). Am J Gastroenterol. 1997;92:407–413
  122. Avidan B, Sonnenberg A, Schnell T, Chejfec G, Metz A, Sontag S. Hiatal hernia size, Barrett’s length, and severity of acid reflux are all risk factors for esophageal adenocarcinoma. Am J Gastroenterol. 2002;97:1930–1936
  123. Cameron AJ, Carpenter HA. Barrett’s esophagus, high-grade dysplasia, and early adenocarcinoma (a pathological study). Am J Gastroenterol. 1997;92:586–591
  124. McArdle JE, Lewin KJ, Randall G, Weinstein W. Distribution of dysplasias and early invasive carcinoma in Barrett’s esophagus. Hum Pathol. 1992;23:479–482
  125. Reid BJ, Weinstein WM, Lewin KJ, Haggitt RC, VanDeventer G, DenBesten L, et al. Endoscopic biopsy can detect high-grade dysplasia or early adenocarcinoma in Barrett’s esophagus without grossly recognizable neoplastic lesions. Gastroenterology. 1988;94:81–90
  126. Weston AP, Sharma P, Topalovski M, Richards R, Cherian R, Dixon A. Long-term follow-up of Barrett’s high-grade dysplasia. Am J Gastroenterol. 2000;95:1888–1893
  127. Falk GW, Rice TW, Goldblum JR, Richter JE. Jumbo biopsy forceps protocol still misses unsuspected cancer in Barrett’s esophagus with high-grade dysplasia. Gastrointest Endosc. 1999;49:170–176
  128. Reid BJ, Blount PL, Feng Z, Levine DS. Optimizing endoscopic biopsy detection of early cancers in Barrett’s high-grade dysplasia. Am J Gastroenterol. 2000;95:3089–3096
  129. Spechler SJ, Lee E, Ahnen D, Goyal RK, Hirano I, Ramirez F, et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease (follow-up of a randomized controlled trial). JAMA. 2001;285:2331–2338
  130. Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS. Is there publication bias in the reporting of cancer risk in Barrett’s esophagus?. Gastroenterology. 2000;119:333–338
  131. Conio M, Cameron AJ, Romero Y, Branch CD, Schleck CD, Burgart LJ, et al. Secular trends in the epidemiology and outcome of Barrett’s oesophagus in Olmsted County, Minnesota. Gut. 2001;48:304–309
  132. Rabinovitch PS, Longton G, Blount PL, Levine DS, Reid BJ. Predictors of progression in Barrett’s esophagus III (baseline flow cytometric variables). Am J Gatroenterol. 2001;96:3071–3083
  133. Reid BJ, Prevo LJ, Galipeau PC, Sanchez CA, Longton G, Levine DS, et al. Predictors of progression in Barrett’s esophagus II (baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression). Am J Gastroenterol. 2001;96:2839–2848
  134. Teodori L, Gohde W, Persiani M, Ferrario F, Tirindelli Danesi D, Scarpignato C, et al. DNA/protein flow cytometry as a predictive marker of malignancy in dysplasia-free Barrett’s esophagus (thirteen-year follow-up study on a cohort of patients). Cytometry. 1998;34:257–263
  135. Coggi G, Bosari S, Roncalli M, Graziani D, Bossi P, Viale G, et al. p53 Protein accumulation and p53 gene mutation in esophageal carcinoma. A molecular and immunohistochemical study with clinicopathologic correlations. Cancer. 1997;79:425–432
  136. Hamelin R, Flejou JF, Muzeau F, Potet F, Laurent-Puig P, Fekete F, et al. TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett’s esophagus. Gastroenterology. 1994;107:1012–1018
  137. Bani-Hani K, Martin IG, Hardie LF, Mapstone N, Briggs JA, Forman D, et al. Prospective study of cyclin D1 overexpression in Barrett’s esophagus (associating with increased risk of adenocarcinoma). J Natl Cancer Inst. 2000;92:1316–1321
  138. Buttar NS, Wang KK, Sebo TJ, Riehle DM, Krishnadath KK, Lutzke LS, et al. Extent of high-grade dysplasia in Barrett’s esophagus correlates with risk of adenocarcinoma. Gastroenterology. 2001;120:1630–1639
  139. Dar MS, Goldblum JR, Rice TW, Falk GW. Can extent of high grade dysplasia in Barrett’s oesophagus predict the presence of adenocarcinoma at oesophagectomy?. Gut. 2003;52:486–489
  140. Nigro JJ, Hagen JA, DeMeester TR, DeMeester SR, Theisen J, Peters JH, et al. Occult esophageal adenocarcinoma (extent of disease and implications for effective therapy). Ann Surg. 1999;230:433–440
  141. McDonald ML, Trastek VF, Allen MS, Deschamps C, Pairolero PC, Pairolero PC. Barrett’s esophagus (does an antireflux procedure reduce the need for endoscopic surveillance?). J Thorac Cardiovasc Surg. 1996;111:1135–1138
  142. Csendes A, Braghetto I, Burdiles P, Puente G, Korn O, Diaz JC, et al. Long-term results of classic antireflux surgery in 152 patients with Barrett’s esophagus (clinical, radiologic, endoscopic, manometric, and acid reflux test analysis before and late after operation). Surgery. 1998;123:645–657
  143. Klaus A, Hinder RA. Medical therapy versus antireflux surgery in Barrett’s esophagus (what is the best therapeutic approach?). Dig Dis. 2000-01;18:224–231
  144. Hakansson HO, Johnsson F, Johansson J, Kjellen G, Walther B. Development of adenocarcinoma in Barrett’s oesophagus after successful antireflux surgery. Eur J Surg. 1997;163:469–471
  145. DeMeester SR, DeMeester TR. Columnar mucosa and intestinal metaplasia of the esophagus (fifty years of controversy). Ann Surg. 2000;231:303–321
  146. Tseng EE, Wu TT, Yeo CJ, Heitmiller RF. Barrett’s esophagus with high-grade dysplasia. Surgical results of occult esophageal adenocarcinoma: extent of disease and implications for effective therapy. Ann Surg. 1999;230:433–438
  147. Bailey SH, Bull DA, Harpole DH, Rentz JJ, Neumayer LA, Pappas TN, et al. Outcomes after esophagectomy (a ten-year prospective cohort). Ann Thorac Surg. 2003;75:217–222
  148. Hofstetter W, Swisher SG, Correa AM, Hess K, Putnam JB, Ajani JA, et al. Treatment outcomes of resected esophageal cancer. Ann Surg. 2002;236:376–384
  149. Birkmeyer JD, Siewers AE, Finlayson EV, Stukel TA, Lucas FL, Batista I, et al. Hospital volume and surgical mortality in the United States. N Engl J Med. 2002;346:1128–1137
  150. Klinkenberg-Knol EC, Nelis F, Dent J, Snel P, Mitchell B, Prichard P, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease (efficacy, safety and influence on gastric mucosa). Gastroenterology. 2000;118:661–669
  151. Ouatu-Lascar R, Fitzgerald RC, Triadafilopoulos G. Differentiation and proliferation in Barrett’s esophagus and the effects of acid suppression. Gastroenterology. 1999;117: 327-325
  152. Lundell L, Miettinen P, Myrvold HE, Pedersen SA, Liedman B, Hatlebakk JG, et al. Continued (5-year) follow-up of a randomized clinical study comparing antireflux surgery and omeprazole in gastroesophageal reflux disease. J Am Coll Surg. 2001;192:172–181
  153. Yau P, Watson DI, Devitt PG, Game PA, Jamieson GG. Laparoscopic antireflux surgery in the treatment of gastroesophageal reflux in patients with Barrett esophagus. Arch Surg. 2000;135:801–805
  154. Hofstetter WL, Peters JH, DeMeester TR, Hagen JA, DeMeester SR, Crookes PF, et al. Long-term outcome of antireflux surgery in patients with Barrett’s esophagus. Ann Surg. 2001;234:532–539
  155. Bammer T, Hinder R, Klaus A, Trastek VF, Achem SR. Rationale for surgical therapy of Barrett esophagus. Mayo Clin Proc. 2001;76:335–342
  156. Oberg S, Cleark GWB, DeMeester TR. Barrett’s esophagus. Update of pathophysiology and management. Hepatogastroenterology. 1998;45:1348–1356
  157. Corey KE, Schmitz SM, Shaheen NJ. Does a surgical anti-reflux procedure decrease the incidence of esophageal adenocarcinoma in Barrett’s esophagus? A meta-analysis. Am J Gastroenterol. 2003;98:2390–2394
  158. Haag S, Nandurkar S, Talley JN. Regression of Barrett’s esophagus (the role of acid suppression, surgery, and ablative methods). Gastrointest Endosc. 1999;50:229–240
  159. Corley DA, Kerlikowske K, Verma R, Buffler P. Protective association of aspirin/NSAIDs and esophageal cancer (a systematic review and meta-analysis). Gastroenterology. 2003;124:47–56
  160. Thun MJ. NSAIDs and esophageal cancer (ready for trials but not yet broad clinical application). Gastroenterology. 2003;124:246–257
  161. Sharma P, Sampliner RE, Camargo E. Normalization of esophageal pH with high dose proton pump inhibitor therapy does not result in regression of Barrett’s esophagus. Am J Gastroenterol. 1997;92:582–585
  162. Sampliner RE. Effect of up to 3 years of high-dose lansoprazole on Barrett’s esophagus. Am J Gastroenterol. 1994;89:1844–1848
  163. Peters FT, Ganesh S, Kuipers EJ, Sluiter WJ, Klinkenberg-Knol EC, Lamers CB, et al. Endoscopic regression of Barrett’s oesophagus during omeprazole treatment; a randomized double blind study. Gut. 1999;45:489–494
  164. Srinivasan R, Katz PO, Ramakrishnan A, Katzka DA, Vela MF, Castell DO. Maximal acid reflux control for Barrett’s oesophagus (feasible and effective). Aliment Pharmacol Ther. 2001;15:519–524
  165. Wilkinson SP, Biddlestone L, Gore S, Shepherd NA. Regression of columnar-lined (Barrett’s) oesophagus with omeprazole 40 mg daily (results of 5 years of continuous therapy). Aliment Pharmacol Ther. 1999;13:1205–1209
  166. Robertson D, Aldersley M, Shepherd H, Smith CL. Patterns of acid reflux in complicated oesophagitis. Gut. 1987;28:1484–1488
  167. Stein HJ, Barlow AP, DeMeester TR, Hinder RA. Complications of gastroesophageal reflux disease. Role of the lower esophageal sphincter, esophageal acid and acid/alkaline exposure, and duodenogastric reflux. Ann Surg. 1992;216:35–43
  168. Basu KK, Bale R, West KP, De Caestecker JS. Persistent acid reflux and symptoms in patients with Barrett’s oesophagus on proton-pump inhibitor therapy. Eur J Gastroenterol Hepatol. 2002;14:1187–1192
  169. Katz PO, Anderson C, Khoury R, Castell DO. Gastrooesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors. Aliment Pharmacol Ther. 1998;12:1231–1234
  170. Jankowski J, Harrison RF, Perry I, Balkwill F, Tselepis C. Seminar (Barrett’s metaplasia). Lancet. 2000;356:2079–2085
  171. Morris CD, Armstrong GR, Bigley G, Green H, Attwood SE. Cyclooxygenase-2 expression in the Barrett’s metaplasia-dysplasia-adenocarcinoma sequence. Am J Gastroenterol. 2001;96:990–996
  172. Shirvani VN, Quatu-Lascar R, Kaur BS, Omary MB, Triadafilopoulos G. Cyclooxygenase 2 expression in Barrett’s esophagus and adenocarcinoma (ex vivo induction by bile salts and acid exposure). Gastroenterology. 2000;118:487–496
  173. Souza RF, Shewmake K, Beer DG, Cryer B, Spechler SJ. Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells. Cancer Res. 2000;60:5767–5772
  174. Wilkinson SP, Biddlestone L, Gore S, Shepherd NA. Clinical effectiveness of laparoscopic fundoplication in a US community. Am J Med. 2003;114:1–5
  175. Csendes A, Burdiles P, Korn O, Braghetto I, Huertas C, Rojas J. Late results of a randomized clinical trial comparing total fundoplication versus calibration of the cardia with posterior gastropexy. Br J Surg. 2000;87:289–927
  176. Csendes A, Burdiles P, Braghetto I, Korn O, Diaz JC, Rojas J. Early and late results of the acid suppression and duodenal diversion operation in patients with Barrett’s esophagus (analysis of 210 cases). World J Surg. 2002;26:566–576
  177. Ye W, Chow WH, Lagergren J, Yin L, Nyren O. Risk of adenocarcinomas of the esophagus and gastric cardia in patients with gastroesophageal reflux diseases and after antireflux surgery. Gastroenterology. 2001;121:1286–1293
  178. Berenson MM, Johnson TD, Markowitz NR, Buchi KN, Samowitz WS. Restoration of squamous mucosa after ablation of Barrett’s esophageal epithelium. Gastroenterology. 1993;104:1686–1691
  179. Sampliner RE, Hixson LJ, Fennerty MB, Garewal HS. Regression of Barrett’s esophagus by laser ablation in an acid environment. Dig Dis Sci. 1993;38:365–368
  180. Laukka MA, Wang KK. Initial results using low-dose photodynamic therapy in the treatment of Barrett’s esophagus. Gastrointest Endosc. 1995;42:59–63
  181. Overholt BF, Panjehpour M. Barrett’s esophagus (photodynamic therapy for ablation of dysplasia, reduction of specialized mucosa, and treatment of superficial esophageal cancer). Gastro-intest Endosc. 1995;42:64–70
  182. Dumoulin FL, Terjung B, Neubrand M, Scheurlen C, Fischer HP, Sauerbruch T. Treatment of Barrett’s esophagus by endoscopic argon plasma coagulation. Endoscopy. 1997;29:751–753
  183. Mork H, Barth T, Kreipe HH, Kraus M, Al-Taie O, Jakob F, et al. Reconstitution of squamous epithelium in Barrett’s oesophagus with endoscopic argon plasma coagulation (a prospective study). Scand J Gastroenterol. 1998;33:1130–1134
  184. Salo JA, Salminen JT, Kiviluoto TA, Nemlander AT, Ramo OJ, Farkkila MA, et al. Treatment of Barrett’s esophagus by endoscopic laser ablation and antireflux surgery. Ann Surg. 1998;227:40–44
  185. Tigges H, Fuchs KH, Maroske J, Fein M, Freys SM, Muller J, et al. Combination of endoscopic argon plasma coagulation and antireflux surgery for treatment of Barrett’s esophagus. J Gastrointest Surg. 2001;5:251–259
  186. Ackroyd R, Brown NJ, Davis MF, Stephenson TJ, Marcus SL, Stoddard CJ, et al. Photodynamic therapy for dysplastic Barrett’s oesophagus (a prospective, double-blind, randomised, placebo controlled trial). Gut. 2000;47:612–617
  187. Sharma P, Morales TG, Bhattacharyya A, Garewal HS, Sampliner RE. Durability of new squamous epithelium following endoscopic reversal of Barrett’s esophagus. Gastrointest Endosc. 1999;50:159–164
  188. Bryne JP, Armstrong GR, Attwood SE. Restoration of the normal squamous lining in Barrett’s esophagus by argon beam plasma coagulation. Am J Gastroenterol. 1998;93:1810–1815
  189. Overholt BF, Lightdale CJ, Wang K, Canto M, Burdick S, Barr H, et al. International, multicenter, partially blinded, randomized study of the efficacy of photodynamic therapy (PDT) using porfimer solium (POR) for the ablation of high-grade dysplasia (HGD) in Barrett’s esophagus (BE) (results of 24-month follow-up). Gastroenterology. 2003;124:A20; on behalf of 23 other investigators
  190. Overholt BJ, Panjehpour M, Haydek JM. Photodynamic therapy for Barrett’s esophagus (follow-up in 100 patients). Gastrointest Endosc. 1999;49:1–7
  191. Barr H, Shepherd NA, Dix A, Roberts DJ, Tan WC, Krasner N. Eradication of high-grade dysplasia in columnar-lined (Barrett’s) oesophagus by photodynamic therapy with endogenously generated protoporphyrin IX. Lancet. 1996;348:584–585
  192. Gossner L, Stolte M, Sroka R, Rick K, May A, Hahn EG, et al. Photodynamic ablation of high-grade dysplasia and early cancer in Barrett’s esophagus by means of 5-aminolevulinic acid. Gastroenterology. 1998;114:448–455
  193. Pacifico RJ, Wang KK. Role of mucosal ablative therapy in the treatment of the columnar-lined esophagus. Chest Surg Clin N Am. 2002;12:185–203
  194. Nijhawan PK, Wang KK. Endoscopic mucosal resection for lesions with endoscopic features suggestive of malignancy and high-grade dysplasia within Barrett’s esophagus. Gastrointest Endosc. 2000;52:328–332
  195. Ell C, May A, Gossner L, Pech O, Gunter E, Mayer G, et al. Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett’s esophagus. Gastroenterology. 2000;118:670–677
  196. May A, Gossner L, Pech O, Fritz A, Gunter E, Mayer G, et al. Local endoscopic therapy for intraepithelial high-grade neoplasia and early adenocarcinoma in Barrett’s oesophagus (acute-phase and intermediate results of a new treatment approach). Eur J Gastroenterol Hepatol. 2002;14:1085–1091
  197. Pech O, May A, Gossner L, Fritz A, Guenter E, Mayer G, et al. Long-term results of local endoscopic therapy for intraepithelial high-grade neoplasia and early adenocarcinoma in Barrett’s esophagus. Gastrointest Endosc. 2003;57:AB100
  198. Buttar NS, Wang KK, Lutzke LS, Krishnadath KK, Anderson MA. Combined endoscopic mucosal resection and photodynamic therapy for esophageal neoplasia within Barrett’s esophagus. Gastrointest Endosc. 2001;54:682–688
  199. Van Laethem JL, Jagodzinski R, Peny MO, Cremer M, Deviere J. Argon plasma coagulation in the treatment of Barrett’s high-grade dysplasia and in situ adenocarcinoma. Endoscopy. 2001;33:257–261
  200. Gossner L, May A, Stolte G, Seitz G, Hahn EG, Ell C. KTP laser destruction of dysplasia and early cancer in columnar-lined Barrett’s esophagus. Gastrointest Endosc. 1999;49:8–12
  201. Weston AP, Sharma P. Neodymium (yttrium-aluminum garnet contact laser ablation of Barrett’s high grade dysplasia and early adenocarcinoma). Am J Gastroenterol. 2002;97:2998–3006
  202. Sharma P, Jaffe P, Bhattacharyya A, Sampliner R. Fate of high grade dysplasia at 1 year after endoscopic ablation with Nd (YAG laser and electrocautery). Am J Gastroenterol. 2000;95:79

PII: S0016-5085(04)00615-8

doi: 10.1053/j.gastro.2004.04.010

Gastroenterology
Volume 127, Issue 1 , Pages 310-330 , July 2004

Article Tools